Vicore Pharma

Vicore Pharma is a rare disease pharmaceutical company focused on rare lung diseases and related indications. The company currently has three drug development programs: VP01, VP02, and VP03.The VP01 program aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The VP02 program is based on new formulations and delivery routes of existing immunomodulatory compounds ("IMiDs"). The VP02 program focuses on underlying conditions associated with IPF and severe cough. Both programs are also actively evaluating other unmet needs within the field of interstitial lung diseases. The VP03 program includes follow-up molecules to C21.